Keywords
mechanical valve - developing countries - rheumatic disease
Introduction
Rheumatic heart disease (RHD) is the most common cause of heart failure and cardiovascular
mortality in young and socially disadvantaged populations living in the sub-Saharan
region.[1] Recent echocardiography-based studies have reported a prevalence between 15 and
30 cases per thousand people living in this area, which is the highest rate in the
world.[2]
[3]
Although palliative, valve surgery represents the only option for many as the local
preventive measures to limit the incidence of acute rheumatic fever (ARF) and RHD
remains ineffective. However, the ideal valve procedure in rheumatic etiology is still
subject to debate especially among the populations in developing countries. Indeed,
since the early era of valve surgery, nonthrombogenic options are advocated in these
patients to avoid complications associated with lifelong anticoagulation required
after mechanical valve implantation. On the other hand, the high rate of reoperation
resulting from the poor durability of tissue valves in young patients[4] and the suboptimal results of technically demanding valve repair in rheumatic disease[5]
[6]
[7] have potentially supported the use of mechanical valves even in disadvantaged communities.
In fact, the limited access to repeat surgery in low-middle income regions mainly
due to financial constraints and the recent improvement in mechanical valves properties
have further supported an increase in use of mechanical valves for their possible
even though unproven freedom from reoperation.
With the exception of few studies,[8]
[9] reports on the use of mechanical valves in the sub-Saharan populations are anecdotal
mainly due to the great deficit of cardiosurgical institutions in this region.[10]
[11]
This paper reviews the outcomes of patients who underwent mechanical valve replacement
at a unique Central Africa cardiosurgical center,[12] serving one of the world's poorest regions with an estimated population of 40 million.
Patients and Methods
The clinical files of 233 patients who underwent 291 mechanical valve replacements
in our institution between February 2008 and June 2016 were reviewed. Patients with
thoracic aorta surgery, coronary disease and those with history of stroke were excluded.
However, patients with associated valve repair, aortic root enlargement, pericardiectomy,
and atrial septal defect closure were included in the study.
One hundred and seventeen patients underwent mitral valve replacement (MVR group;
n = 117, 50.2%), 57 had aortic valve replacement (AVR group; n = 57, 24.4%) and 59 underwent both aortic and mitral replacement (n = 59, 25.3%, double valve replacement [DVR] group). Rheumatic disease was the most
common etiology (80.6%). Associated procedures were performed in 150 patients (n = 80/117 in MVR, n = 27/57 in AVR, and n = 43/59 in DVR). The clinical characteristics of patients are listed in ([Table 1]).
Table 1
Patient's characteristics and operative data
|
Variables
|
AVR
(n = 57)
|
MVR
(n = 117)
|
DVR
(n = 59)
|
|
Age (y), mean ± SD
|
25.7 ± 12.1
|
27.8 ± 13.3
|
27.6 ± 14.1
|
|
Male sex, n (%)
|
39 (68.4)
|
45 (38.4)
|
36 (61.0)
|
|
Body mass index, kg/m2, mean ± SD
|
23 ± 4.7
|
21.6 ± 5.1
|
22.6 ± 3.8
|
|
Body surface area, m2, mean ± SD
|
1.61 ± 0.3
|
1.49 ± 0.3
|
1.42 ± 0.6
|
|
New York Heart Association class ≥ III, n (%)
|
52 (91.2)
|
99 (84.6)
|
56 (94.9)
|
|
Previous cardiac surgery, n (%)
|
2 (3.5)
|
2 (1.7)
|
0 (0.0)
|
|
Valve regurgitation, n (%)
|
43 (75.4)
|
64 (54.7)
|
–
|
|
Valve stenosis, n (%)
|
4 (7.0)
|
25 (21.3)
|
–
|
|
Mixed valve disease, n (%)
|
10 (17.5)
|
28 (23.9)
|
–
|
|
Rheumatic etiology, n (%)
|
38 (66.6)
|
99 (84.6)
|
51 (86.4)
|
|
Left ventricle ejection fraction, mean ± SD
|
60.9 ± 12.2
|
62.2 ± 12.3
|
57.3 ± 10.7
|
|
Left ventricle ejection fraction < 50%, n (%)
|
7 (12.2)
|
18 (15.4)
|
6 (10.1)
|
|
PAPs, mean ± SD
|
–
|
76.7 ± 23.7
|
75.5 ± 23.0
|
|
Atrial fibrillation, n (%)
|
–
|
28 (23.9)
|
10 (16.9)
|
|
Main concomitant procedures
|
27 (47.3)
|
80 (68.3)
|
43 (72.8)
|
|
Tricuspid valve repair
|
8 (14.0)
|
76 (64.9)
|
27 (45.7)
|
|
Mitral repair
|
11 (19.2)
|
–
|
–
|
|
Aortic repair
|
–
|
4 (3.4)
|
–
|
|
Aortic annulus enlargement
|
8 (14.0)
|
–
|
16 (27.1)
|
|
Cardiopulmonary bypass time (min), mean ± SD
|
101.3 ± 54.5
|
118.2 ± 64.2
|
173.7 ± 79.6
|
|
Cross clamping time (min), mean ± SD
|
66.7 ± 33.3
|
75.6 ± 47.6
|
125.8 ± 68.7
|
|
Intensive care unit stay (h), mean ± SD
|
58.3 ± 30.6
|
75.3 ± 34.8
|
86.9 ± 49.3
|
|
Hospital stay (d), mean ± SD
|
16.5 ± 5.1
|
15.9 ± 3.6
|
17.2 ± 4.4
|
|
Hospital death (30-d mortality), n (%)
|
2 (3.5)
|
6 (5.1)
|
3(5.0)
|
Abbreviation: PAPs, systolic pulmonary artery pressure.
The institutional review board approved the study and the consent form was waived
for this retrospective study.
Sponsorship and Planning of Surgeries
Due to the absence of a local healthcare coverage and the lower-middle income status
of the country, few patients are able to afford their medical care (Cameroon Per-capita
Gross National Income in 2014: 1,360 USD; minimum annual salary: 583 USD; mean cost
of heart surgery: 5,348 USD). A social case office was created with the contribution
of local and international nongovernmental organizations (NGO) to assist the underprivileged
patients. Since 2011, this system has covered more than 88% of patients who had heart
surgery in our institution although only one-third of the patients on our waiting
surgical list have benefited from it.
The surgical activities started in 2005 during surgical missions by foreign teams.
A total of 47 foreign surgical teams have visited the institution during the study
period including 25 and 22 pediatric and adults' missions respectively. Following
the recruitment of a Cameroonian born adult senior surgeon in 2013, the autonomy of
the local team was empowered with consequent reduction of visiting teams for acquired
heart disease (AHD). Thus, the local team has been fully autonomous since 2013 with
regards to the surgical treatment of patients with AHD. However, the pediatric missions
have continued as well as the periodical visits (1–6 months) of foreign anesthesiologists
to support the young local anesthesiology staff. Between 2009 and 2011, the surgeries
performed by the local team represented only 1% of the surgical activities, whereas
this percentage increased to ∼45% (98% AHD surgery) during the last 2 years of the
study.
Surgical Technique
Intraoperative transesophageal echocardiography was routinely used in all the patients
to assess the morphology and the function of the cardiac valves. A full median sternotomy
was performed in all cases. Cardiopulmonary bypass was established through the cannulation
of the ascending aorta and right atrium or both caval veins according to the specific
procedure. The mode of administration and the type of cardioplegic solution either
crystalloid (mainly Custodiol HTK solution) or warm blood were chosen according to
the preference of the surgeon. The mitral valve was approached mainly through a standard
left atriotomy whereas a supracoronary “Hockey Stick” aortotomy was done in the majority
of aortic procedures. The decision to replace the valve was taken by the senior surgeon
and the model of the mechanical prosthesis was chosen based mainly on availability
at the time of the surgery (On-X valves in 82.1% of patients; [Fig. 1]). In patients who underwent mitral replacement, subvalvular apparatus was maintained
whenever possible. The posterior mitral leaflet was preserved in cases with less fibrotic
involvement especially and in presence of impaired preoperative left ventricular function.
In alternative, artificial PTFE chords implantation was performed after complete resection
of fibrotic or calcified sub-valvular apparatus. Aortic valves were implanted in the
supraannular position in all cases.
Fig. 1 Mechanical valves data—models and sizes. AP, advance performance; AVR, aortic valve
replacement; DVRa, aortic prosthesis in double valve replacement; DVRm, mitral prosthesis
in double valve replacement; MVR, mitral valve replacement; SJM HP, St Jude Medical
Hemodynamic Plus.
Follow-up
All patients received oral anticoagulation from the first postoperative day when possible
following a target International Normalized Ratio (INR) of 2.5 to 3.5 for MVR and
DVR groups and 2.0 to 3.0 for AVR group. In cases with controlled bleeding, concomitant
subcutaneous injections of low-molecular weight heparin (Clexane, SANOFI: 60–100 UI/kg twice daily) were administrated from the first postoperative
day as bridging anticoagulant therapy. All patients had postoperative transthoracic
echocardiogram before discharge and during follow-up in our outpatient department
or during external screening campaigns in remote areas. Other information was collected
by interview to the patient's physicians or cardiologist. A monthly INR control was
recommended in all the patients whenever possible. The mean global clinical follow-up
was 839 patient-years (range: 1–9.4 years) and it was 93% complete (16 [7%] of the
222 patients who were discharged from the hospital were lost at follow-up).
Assessment of Patient's Compliance
To assess the compliance to oral anticoagulation therapy at follow-up, we classified
the patients in three different groups according to both the regularity of oral anticoagulation
intake and the INR control ([Table 2]).
Table 2
Compliance to anticoagulation therapy at follow-up
|
Status
|
AVR
(n = 52)
|
MVR
(n = 101)
|
DVR
(n = 53)
|
Total
(n = 206)
|
|
-Regular intake of OAT
-Monthly INR control
|
13
|
32
|
15
|
60 (29.1%)
|
|
-Regular intake of OAT
-INR control (>1 ≤ 3 mo)
|
32
|
54
|
29
|
115 (55.8%)
|
|
-Discontinued intake of OAT
-INR control (> 3 mo)
|
7
|
15
|
9
|
31 (15.0%)
|
Abbreviations: INR, international normalized ratio; OAT, oral anticoagulation therapy.
Statistical Analysis
Statistical analysis was performed with StatView 4.5 (SAS Institute Inc, Abacus Concepts,
Berkeley, California, United States). Overall survival, freedom from valve and anticoagulation
related events (bleeding, thromboembolism, reoperation, endocarditis, and neurologic
events) were expressed as mean values ± 1 standard deviation, and computed by using
the Kaplan–Meier method. Differences among curves were analyzed by means of the log-rank
Mantel-Cox test. For all statistical analysis a p-value < 0.05 was considered significant. Hospital deaths and lost at follow-up were
included in the survival analysis. The patients lost at follow-up were included in
the survival analysis up to their last period of control.
Results
In-Hospital Mortality
The overall 30-day mortality was 4.7% (11/233); by groups: AVR = 2 (3.5%), MVR = 6
(5.1%), DVR = 3 (5%). Six deaths were due to postoperative low cardiac output syndrome
whereas other causes were pneumonia (n = 1), acute renal failure (n = 1), sudden death (n = 2) and pulmonary embolism (n = 1).
Survival
Twenty nine late deaths were recorded (AVR = 3; MVR = 18; DVR = 8) reporting a 1 and
6-year survival for the whole cohort of 88.8 ± 2.1% and 78.7 ± 3.3%, respectively
([Fig. 2A]). The 6-year survival divided by groups was 89.3 ± 4.8%, 73.2 ± 5.4% and 79.3 ± 5.8%
for AVR, MVR, and DVR, respectively ([Fig. 2B]). The Log-rank test did not detect any significant difference between the groups
(p = 0.15). The causes of death at follow-up are listed in ([Table 3]).
Table 3
Causes of deaths at follow-up
|
Causes of death
|
AVR
|
MVR
|
DVR
|
|
Heart failure
|
1
|
8
|
3
|
|
Endocarditis
|
1
|
–
|
1
|
|
Bleeding
|
–
|
2
|
–
|
|
Stroke
|
–
|
4
|
1
|
|
Sudden death
|
1
|
1
|
1
|
|
Unknown
|
|
3
|
2
|
|
Total
|
3
|
18
|
8
|
Abbreviations: AVR, aortic valve replacement; DVR, double valve replacement; MVR,
mitral valve replacement.
Fig. 2 Survival of the whole cohort and the expected survival of the Cameroonian population
aged 25–29 years (A) Survival according to valve procedure (B).
Valve-Related Events
The 1- and 6-year freedom from bleeding for the whole study was 98.6 ± 0.8% and 78.9 ± 3.7%,
respectively (6-year for the groups: AVR: 80.5 ± 7.7%; MVR: 78.6 ± 5.2%; DVR: 71.5 ± 9.0%,
p = 0.53; [Fig. 3A] and [B]). Two patients with major bleeding (gastrointestinal) died at follow-up.
Fig. 3 Freedom from anticoagulation related bleeding: whole cohort (A) and procedure related (B).
Prosthetic valve endocarditis was reported in two patients at follow-up. One patient
who underwent AVR for aortic endocarditis presented 8 months after with persistent
fever and vegetations on the mitral valve. A second patient with Human Immunodeficiency
Virus infection who had DVR presented with prosthetic aortic valve endocarditis three
months after surgery.
No case of prosthesis thrombosis was observed at follow-up.
Freedom from Neurologic Events
Twelve patients experienced neurologic events at follow-up and five of these events
were fatal. The 1 and 6-year freedom from neurologic injury was 98.6 ± 0.8% and 93.1 ± 2.1%
for the whole cohort ([Fig. 4A]). The 6-year freedom for neurologic events according to valve procedure was 100%,
91.1 ± 3.0%, 90.9 ± 5.2% for AVR, MVR, and DVR respectively ([Fig. 4B]).
Fig. 4 Freedom from neurologic events at 1 and 6 years: whole cohort (A) and procedure related (B).
Echocardiography Results
Three patients who received a 17 mm aortic prosthesis (St. Jude Medical, Hemodynamic
Plus) reported moderate patient-prosthesis mismatch (Indexed Effective Orifice Area
0.65–0.85 cm2/m2) at follow-up, whereas five patients who underwent MVR had moderate aortic regurgitation
(AR) at follow-up as progression of mild AR at surgery. None of these patients reported
significant symptoms requiring reoperation.
Pregnancies
Eight full-term pregnancies and five abortions were reported in 10 patients at follow-up.
Five of the 8 patients who had full term pregnancy maintained oral anticoagulation
therapy throughout their pregnancies and had subcutaneous heparin only a few days
before Caesarean delivery. No cases of anticoagulation-related embryopathy were reported.
Patient's Compliance
Approximately 85% of the patients observed at follow-up (n = 175/206) were judged compliant with oral anticoagulation therapy ([Table 2]). The 6-year freedom from cardiovascular events (cardiac death, endocarditis, bleeding,
and neurologic events) suggested an increased complication rate among the noncompliant
patients (55.5 ± 10.6%) as compared with the compliant group (66.6 ± 4.5%) although
this difference was not found statistically significant (p = 0.16) ([Fig. 5]).
Fig. 5 Comparative event-free survival (cardiac death, stroke, bleeding, endocarditis) of
compliant and noncompliant patients. C, compliant; NC, noncompliant.
Discussion
In recent years, significant improvements have been made in mechanical heart valve
properties, along with better hemodynamic performance and low thrombogenicity. However,
their use in poorly compliant populations especially in low-income countries remains
controversial for the lack of anticoagulation management facilities and the disadvantaged
socio-economic environment that have been associated with major risk of prosthetic
valve related complications.[13]
[14]
Are mechanical valves safe enough to be used in the Sub-Saharan population? The reality
is that little is known as few data have been presented in the medical literature.
This scarcity of data reflects the lack of heart specialists and specialized centers
in this region,[10]
[11]
[15]
[16] one of the poorest in the world. The shortage of medical infrastructure, the extreme
poverty and the cultural complexity expressed by patient's poor compliance, inexorably
suggest a cautious selection of the surgical procedures to this particular environment.
In the Sub-Saharan region, valvular diseases are predominantly of rheumatic origin
with a high prevalence among young patients from disadvantaged populations.[1]
[3] In this subgroup, tissue valves and conservative techniques are limited by a poor
durability due to early structural valve deterioration and repair failure over time.[4]
[5]
[6]
[7]
[17] Thus, for many patients, mechanical valve replacement could represent an attractive
compromise despite the risk of associated complications.
In our series, the choice of mechanical prosthesis was driven by several factors.
First, the relatively young age of our cohort (mean age: 27.6 ± 13.4 years) and the
predominance of rheumatic etiology (80.6%). Second, the expected compliance and the
facilities of patients and relatives to attend postoperative visits and medical therapy
in our institution were judged acceptable. Third, the limited financial resources
have potentially supported the choice of mechanical valves as costs arising from reoperation
would have not been affordable in many cases. Indeed, in the absence of a local healthcare
system, more than 88% of our patients were financially supported by private NGOs for
their surgery. However, only 35% of the patients of our waiting list benefits from
this sponsorship. Thus, it is difficult to guarantee multiple supports for a single
case. Lastly but not the least, it is possible that the rate of valve replacement
was also linked to surgeon factors.[18]
[19] During the first 3 years of the study period, a great number of valve procedures
were performed by foreign surgeons during surgical missions. With few exceptions,
the surgeons' experience in rheumatic valve disease was limited.
The operative mortality was 4.7%. This ranges between 2.3 and 8.2% in series in similar
populations.[9]
[20] Furthermore, our mortality rate was comparable with reports from the EACTS and STS
databases[21] ranging between 2.9 and 3.7% and 4.3 and 6% for AVR and MVR, respectively (3.5–5.1%
in our study). Consistent with findings in a West African experience,[8] the progression of heart failure was a common cause of death (41%) in our cohort
at follow-up, especially in patients who had impaired ventricular function prior to
surgery as a result of late referral due to both socio-cultural habits and the limited
access to specialized institutions.
Approximately 85% of our patients at follow-up were judged compliant with oral anticoagulation
therapy ([Table 2]). This ranges between 40 and 56% in previous series in similar populations.[9]
[22] We think the location of the institution in a rural area where the majority of our
patients are living and our external screening campaigns in remote areas were supporting
factors for patient's compliance.
The overall freedom from anticoagulation related bleeding was 78.9 ± 3.7% at 6-year.
This was higher than previous reports from others third world populations[9]
[20] and accounted for 6.8% (2/29) of the deaths at follow-up. We think the rate of bleeding
was linked to the intensity of anticoagulation therapy in our cohort as reported by
others.[23]
Freedom from neurologic injury was similar to previous reports in western populations.
However, the diagnosis of stroke was done clinically as the etiology (hemorrhagic
or ischemic) of such events was not clearly defined in the majority of our patients
for the lack of diagnostic facilities (CT scan, MRI).
Thus, no case of valve thrombosis was documented at follow-up, although we could not
exclude this complication in patients who had sudden death or in those where the cause
of death was unknown. This unexpected low incidence of prosthetic valve thrombosis
could be linked to both the acceptable compliance in our cohort and the use of On-X
mechanical valves (82.1% of patients). Although in poorly-anticoagulated patients,
low rates of prosthetic valve thrombosis have been previously reported with the On-X
valves when compared with other mechanical valves models.[9]
[22]
[24] Williams et al[9] reported a freedom from thromboembolism of 84% at 4 years using On-X valves even
though only 56% of their patients were judged compliant with anticoagulation therapy.
Furthermore, the Food and Drugs Administration has recently approved the use of On-X
valves in the aortic position[25] with lower INR values (1.5–2.0 instead of 2.0–3.0). These reports emphasize on the
key role of careful prosthesis selection in a setting where inadequate anticoagulation
might be a factor.
No patient underwent reoperation, either on the implanted prosthesis or for other
cardiac disease. This is consistent with the low rate of prosthetic valve events reported
at follow-up. None of the patients with mitral prosthesis had significant patient-prosthesis
mismatch (PPM) at follow-up. This was partly related to the implantation of adult
size prosthesis in the majority of our young patients ([Fig. 1]) without requiring alternative techniques such as supra-annular implantation. The
latter is a valuable alternative when conventional annular mitral replacement is not
feasible in small native annulus despite it has been associated with increased morbidity
including a significant risk of reoperation.[26] However, 3 of the 4 patients who received a 17 mm St. Jude HP valve in aortic position
had moderate PPM (Indexed Effective Orifice Area 0.65–0.85 cm2/m2) and five patients with MVR presented with moderate AR at follow-up as progression
of mild AR at surgery although no significant symptoms were reported in none of these
patients.
Ten patients reported eight full-term pregnancies and five spontaneous abortions.
No case of embryopathy was diagnosed among the eight pregnancies. Five of the eight
women who delivered maintained oral anticoagulation until a few days prior to Caesarean
delivery. One of these patients had severe postcaesarean bleeding requiring hysterectomy.
Our current policy is to maintain oral anticoagulation throughout the whole pregnancy.
The administration of unfractionated intravenous heparin is started only few days
before a programmed caesarean delivery. First, because the home management of unfractionated
intravenous heparin and low molecular weight heparin in our patients may be somewhat
troublesome requiring careful monitoring. Second, their effectiveness to prevent thrombosis
and thromboembolism in pregnant women with prosthetic heart valves remains questionable
as fatal maternal and fetal events have been reported even at therapeutic doses compared
with oral anticoagulation.[27]
[28]
[29] Lastly, the rate of warfarin embryopathy was low in various series and seems to
be dose dependent, with low risk with a daily dose of ≤ 5 mg.[30]
Limitations of the study were those associated with retrospective studies. Moreover,
the limited number of patients and the shorter length of follow-up do not permit conclusions
on long-term outcomes, which will be important for this young patient population.
Conclusion
Our preliminary experience suggests acceptable mid-term outcomes in patients with
mechanical heart valves in our region. Both accurate surgical evaluation and strategies,
either financial or social, facilitating patient education and assistance are crucial
to ensure good results. Long-term follow-up and prospective studies comparing current
nonthrombogenic surgical options are warranted to draw reliable conclusions.
